Abstract
Mast cell is a hematopoietic lineage dependent on Kit signaling for growth, differentiation, and survival. Mast cells are found in excessive numbers in tissues in a heterogeneous group of disorders collectively known as mastocytosis. Last decade has witnessed important advancements in our understanding of the molecular pathology of mastocytosis. First, systemic mastocytosis has been found to be associated with activating codon 816 mutations of the c-kit gene. Second, this mutation was used as a tracking marker to elucidate the clonal nature of mastocytosis. These findings have resulted in consideration of systemic mastocytosis as a clonal neoplastic disorder of a hematopoietic progenitor cell. Improved knowledge of the mechanisms causing pathological mast cell growth will lead to the discovery of novel treatment options including drugs targeting the mutated Kit protein.
References
1.
Ehrlich P: Beiträge zur Kenntniss der granulirten Bindegewebezellen und der eosinophilen Leukocythen. Arch Anat Physiol Physiol Abt 1879;3:166.
2.
Ginsburg H, Sachs L: Formation of pure suspensions of mast cells in tissue culture by differentiation of lymphoid cells from the mouse thymus. J Natl Cancer Inst 1962;31:1.
3.
Ginsburg H, Lagunoff D: The in vitro differentiation of mast cells. Cultures of cells from immunized mouse lymph nodes and thoracic duct lymph on fibroblast monolayers. J Cell Biol 1967;35:685–697.
4.
Ishizaka T, Okudaira H, Mauser LE, Ishizaka K: Development of rat mast cells in vitro. I. Differentiation of mast cells from thymus cells. J Immunol 1976;116:747–754.
5.
Kitamura Y, Shimada M, Hatanaka K, Miyano Y: Development of mast cells from grafted bone marrow cells in irradiated mice. Nature 1977;268:442–443.
6.
Kitamura Y, Go S, Hatanaka K: Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978;52:447–452.
7.
Kitamura Y, Shimada M, Go S, Matsuda H, Hatanaka K, Seki M: Distribution of mast-cell precursors in hematopoeitic and lymphopoietic tissues of mice. J Exp Med 1979;150:482–490.
8.
Galli SJ, Tsai M, Wershil BK: The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol 1993;142:965–974.
9.
Kitamura Y, Go S: Decreased production of mast cells in Sl/Sld anemic mice. Blood 1979;53:492–497.
10.
Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A: The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988;335:88–89.
11.
Geissler EN, Ryan MA, Housman DE: The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 1988;55:185–192.
12.
Williams DE, Eisenman J, Baird A, Rauch C, Van Ness K, March CJ, Park LS, Martin U, Mochizuki DY, Boswell HS, Burgess GS, Cosman D, Lyman SD: Identification of a ligand for the c-kit proto-oncogene. Cell 1990;63:167–174.
13.
Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, Hsu RY, Birkett NC, Okino KH, Murdock DC, Jakobsen FW, Langley KE, Smith KA, Takeishi T, Cattanach BM, Galli SJ, Suggs SV: Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990;63:213–224.
14.
Huang E, Nocka K, Beier DR, Chu TY, Buck J, Lahm HW, Wellner D, Leder P, Besmer P: The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990;63:225–233.
15.
Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman L, Snyder HW, Jr, Brodeur D, Zuckerman EE, Hardy WD: A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986;320:415–421.
16.
Nocka K, Tan JC, Chiu E, Chu TY, Ray P, Traktman P, Besmer P: Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W. EMBO J 1990;9:1805–1813.
17.
Huang EJ, Nocka KH, Buck J, Besmer P: Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. Mol Biol Cell 1992;3:349–362.
18.
Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R: Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 2005;23:16–43.
19.
Scheijen B, Griffin JD: Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 2002;21:3314–3333.
20.
Valent P, Spanblochl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P, Lechner K: Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 1992;80:2237–2245.
21.
Kirshenbaum AS, Goff JP, Kessler SW, Mican JM, Zsebo KM, Metcalfe DD: Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol 1992;148:772–777.
22.
Lin TJ, Bissonnette EY, Hirsh A, Befus AD: Stem cell factor potentiates histamine secretion by multiple mechanisms, but does not affect tumour necrosis factor-alpha release from rat mast cells. Immunology 1996;89:301–307.
23.
Bischoff SC, Schwengberg S, Raab R, Manns MP: Functional properties of human intestinal mast cells cultured in a new culture system: Enhancement of IgE receptor-dependent mediator release and response to stem cell factor. J Immunol 1997;159:5560–5567.
24.
Yanagida M, Fukamachi H, Ohgami K, Kuwaki T, Ishii H, Uzumaki H, Amano K, Tokiwa T, Mitsui H, Saito H, Iikura Y, Ishizaka T, Nakahata T: Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 1995;86:3705–3714.
25.
Akin C, Brockow K, D’Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, Metcalfe DD: Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003;31:686–692.
26.
Butterfield JH, Weiler D, Dewald G, Gleich GJ: Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988;12:345–355.
27.
Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y, Kanakura Y: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736–1744.
28.
Tsujimura T, Furitsu T, Morimoto M, Isozaki K, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y: Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 1994;83:2619–2626.
29.
Tsujimura T, Furitsu T, Morimoto M, Kanayama Y, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y: Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int Arch Allergy Immunol 1995;106:377–385.
30.
Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92:10560–10564.
31.
Pignon JM, Giraudier S, Duquesnoy P, Jouault H, Imbert M, Vainchenker W, Vernant JP, Tulliez M: A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 1997;96:374–376.
32.
Pullarkat VA, Pullarkat ST, Calverley DC, Brynes RK: Mast cell disease associated with acute myeloid leukemia: Detection of a new c-kit mutation Asp816His. Am J Hematol 2000;65:307–309.
33.
Longley BJ Jr, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu S, Heitjan D, Ma Y: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999;96:1609–1614.
34.
Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD: A novel form of mastocytosis associated with a transmembrane c-Kit mutation and response to imatinib. Blood 2004;103:3222–3225.
35.
Tang X, Boxer M, Drummond A, Ogston P, Hodgins M, Burden AD: A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J Med Genet 2004;41:e88.
36.
Buttner C, Henz BM, Welker P, Sepp NT, Grabbe J: Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behavior. J Invest Dermatol 1998;111:1227–1231.
37.
Beghini A, Tibiletti MG, Roversi G, Chiaravalli AM, Serio G, Capella C, Larizza L: Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001;92:657–662.
38.
Valent P, Akin C, Sperr W, Mayerhofer M, Fodinger M, Fritsche-Polanz R, Sotlar K, Escribano L, Arock M, Horny HP, Metcalfe D: Mastocytosis: Pathology, genetics, and current options for therapy. Leuk Lymphoma 2005;46:35–48.
39.
Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, Modlin I: Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312–314.
40.
Krober SM, Horny HP, Ruck P, Kammerer U, Geiselhart A, Handgretinger R, Griesser H, Menke DM, Kaiserling E: Mastocytosis: Reactive or neoplastic? J Clin Pathol 1997;50:525–527.
41.
Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD: Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000;28:140–147.
42.
Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C: Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002;100:661–665.
43.
Pardanani A, Reeder T, Li CY, Tefferi A: Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 2003;27:883–885.
44.
Kocabas CN, Yavuz AS, Lipsky PE, Metcalfe DD, Akin C: Analysis of the lineage relationship between mast cells and basophils employing the c-kit D816V mutation as a biologic signature. J Allergy Clin Immunol 2005; in press.
45.
Metcalfe DD, Akin C: Mastocytosis: Molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001;25:577–582.
46.
Isozaki K, Terris B, Belghiti J, Schiffmann S, Hirota S, Vanderwinden JM: Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000;157:1581–1585.
47.
Robson ME, Glogowski E, Sommer G, Antonescu CR, Nafa K, Maki RG, Ellis N, Besmer P, Brennan M, Offit K: Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res 2004;10:1250–1254.
48.
Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, Kuraishi A, Mori H, Matsuda Y, Wada S, Sodeyama H, Nakata S, Kawamura N, Hata S, Watanabe M, Iijima Y, Katsuyama T: Familial gastrointestinal stromal tumor with hyperpigmentation: Association with a germline mutation of the c-kit gene. Gastroenterology 2001;120:210–215.
49.
Sommer G, Agosti V, Ehlers I, Rossi F, Corbacioglu S, Farkas J, Moore M, Manova K, Antonescu CR, Besmer P: Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci USA 2003;100:6706–6711.
50.
Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H, Sugahara H, Mitsui H, Kanayama Y, Kitamura Y, Matsuzawa Y: Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995;85:790–798.
51.
Kitayama H, Tsujimura T, Matsumura I, Oritani K, Ikeda H, Ishikawa J, Okabe M, Suzuki M, Yamamura K, Matsuzawa Y, Kitamura Y, Kanakura Y: Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood 1996;88:995–1004.
52.
Ferrao PT, Gonda TJ, Ashman LK: Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver. Leuk Res 2003;27:547–555.
53.
Baldus SE, Zirbes TK, Thiele J, Eming SA, Henz BM, Hartmann K: Altered apoptosis and cell cycling of mast cells in bone marrow lesions of patients with systemic mastocytosis. Haematologica 2004;89:1525–1527.
54.
Taylor ML, Dastych J, Sehgal D, Sundstrom M, Nilsson G, Akin C, Mage RG, Metcalfe DD: The Kit-activating mutation D816V enhances stem cell factor- dependent chemotaxis. Blood 2001;98:1195–1199.
55.
Akin C, Jaffe ES, Raffeld M, Kirshenbaum AS, Daley T, Noel P, Metcalfe DD: An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: Expression of stem cell factor by lesional mast cells. Am J Clin Pathol 2002;118:242–247.
56.
Taylor ML, Sehgal D, Raffeld M, Obiakor H, Akin C, Mage RG, Metcalfe DD: Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. J Mol Diagn 2004;6:335–342.
57.
Columbo M, Horowitz EM, Botana LM, MacGlashan DW Jr, Bochner BS, Gillis S, Zsebo KM, Galli SJ, Lichtenstein LM: The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J Immunol 1992;149:599–608.
58.
Frenz AM, Gibbs BF, Pearce FL: The effect of recombinant stem cell factor on human skin and lung mast cells and basophil leukocytes. Inflamm Res 1997;46:35–39.
59.
Daley T, Metcalfe DD, Akin C: Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin. Blood 2001;98:880–882.
60.
Nilsson G, Miettinen U, Ishizaka T, Ashman LK, Irani AM, Schwartz LB: Interleukin-4 inhibits the expression of Kit and tryptase during stem cell factor-dependent development of human mast cells from fetal liver cells. Blood 1994;84:1519–1527.
61.
Xia HZ, Du Z, Craig S, Klisch G, Noben-Trauth N, Kochan JP, Huff TH, Irani AM, Schwartz LB: Effect of recombinant human IL-4 on tryptase, chymase, and Fc epsilon receptor type I expression in recombinant human stem cell factor-dependent fetal liver-derived human mast cells. J Immunol 1997;159:2911–2921.
62.
Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E, Mecucci C: C-kit mutations in core binding factor leukemias. Blood 2000;95:726–727.
63.
Carter MC, Metcalfe DD: Paediatric mastocytosis. Arch Dis Child 2002;86:315–319.
64.
Spritz RA: Molecular basis of human piebaldism. J Invest Dermatol 1994;103:S137–S140.
65.
Sotlar K, Escribano L, Landt O, Mohrle S, Herrero S, Torrelo A, Lass U, Horny HP, Bultmann B: One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003;162:737–746.
66.
Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA, Rao VK, Metcalfe DD: Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res 2003;27:677–682.
67.
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201–1214.
68.
Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB: Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003;3:3.
69.
Tefferi A, Lasho TL, Brockman SR, Elliott MA, Dispenzieri A, Pardanani A: FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica 2004;89:871–873.
70.
Akin C, Metcalfe DD: The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004;114:13–19; quiz 20.
71.
Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, Tefferi A: Imatinib for systemic mast-cell disease. Lancet 2003;362:535–536.
72.
Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB: Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004;103:473–478.
73.
Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ: The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99:1741–1744.
74.
Zermati Y, De Sepulveda P, Feger F, Letard S, Kersual J, Casteran N, Gorochov G, Dy M, Ribadeau Dumas A, Dorgham K, Parizot C, Bieche Y, Vidaud M, Lortholary O, Arock M, Hermine O, Dubreuil P: Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003;22:660–664.
75.
Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925–932.
76.
Afonja O, Amorosi E, Ashman L, Takeshita K: Multilineage involvement and erythropoietin-‘independent’ erythroid progenitor cells in a patient with systemic mastocytosis. Ann Hematol 1998;77:183–186.
77.
Sotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R, Stein H, Valent P, Horny HP: Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol 2000;53:188–193.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
